Working… Menu

Treatment of Patients With Type 2 Diabetes With an Interleukin-1 Antagonist

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00303394
Recruitment Status : Completed
First Posted : March 16, 2006
Last Update Posted : March 5, 2007
Steno Diabetes Center Copenhagen
Information provided by:
University of Zurich

Brief Summary:

Aim: To investigate the therapeutic potential of IL-1Ra in type 2 diabetes.

Rationale: Since the major defect leading to a decrease in b-cell mass in type 2 diabetes is increased apoptosis, therapeutic approaches designed to arrest apoptosis could be a significant new development in its management. This approach might actually reverse the disease to a degree rather than just palliate glycemia. Based on current thinking, treatment with IL-1Ra appears as a promising approach. The prospected effect is blocking of the IL-1b-mediated glucotoxicity and thereby to prevent the decline in b-cell mass, together with a rapid restoration of b-cell function. FDA approval for IL-1Ra in the treatment of rheumatoid arthritis occurred based on a favourable tolerability profile.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Drug: IL-1Ra Phase 2

Detailed Description:
Methodology: This will be a two-centre (University Hospital, Zurich, Switzerland and Steno Diabetes Center, Gentofte, Denmark) study. 72 patients will be randomised according to a double-blind, placebo-controlled protocol in which half of the patients are treated with IL-1Ra, the other half with saline. The treatment period will last 13 weeks. This time-period should be sufficient for reversal of functional glucotoxicity and feasible in terms of patient compliance. Whether 13 weeks of treatment will be sufficient to make significant changes in b-cell mass in unpredictable. However, blocking b-cell apoptosis, while new islet formation and b-cell replication are normal, may initiate enlargement of b-cell mass, which may progress beyond the treatment period. Patient evaluation will be performed at start and after 4, 13, 26, 39 and 52 weeks. Following 13 weeks, patients with a fasting plasma glucose levels > 8 mM or with a glycosylated hemoglobin level (HbA1c) > 8% will be treated with insulin. Insulin treatment will not be initiated earlier to avoid interference with possible effects of insulin on primary outcome in the period where the largest effect of IL-1Ra are expected. To assess effects of IL-1Ra on insulin sensitivity, a subset of 40 patients (20 IL-1Ra- and 20 placebo-treated) will undergo an euglycemic-hyperinsulinemic clamp as well as a muscle and fat biopsy at start and after the end of treatment (13 weeks). The Ethics Committee of both centres have already approved the procedure.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Phase 2 Study of IL-1Ra in Patients With Type 2 Diabetes
Study Start Date : April 2004
Study Completion Date : March 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Anakinra

Primary Outcome Measures :
  1. HbA1c

Secondary Outcome Measures :
  1. Insulin requirement
  2. Stimulated C peptide and insulin
  3. Fasting plasma glucose (FPG)
  4. Serum cytokine levels, CRP
  5. Insulin secretion and Insulin-sensitivity index derived from an OGTT with insulin and glucose measurements.
  6. In a subgroup of patients, insulin-sensitivity assessed by clamp techniques
  7. Insulin signaling- and cytokine- gene expression profiles derived from muscle and fat biopsy samples.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age >20
  • Diabetes mellitus Type 2 (American Diabetes Association criteria) of at least 3 months duration
  • HbA1c >7.5%
  • Body-mass index (BMI) > 27

Exclusion Criteria:

  • Positive GAD 65 or IA-2 antibodies at inclusion.
  • HbA1c >12%, polyuria and thirst (exclusion of severely decompensated patients)
  • C-peptide < 400pmol/l (basal )
  • Established anti-inflammatory therapy (includiung cortisone, NSAID, Cox-2-inhibitor). Low dose aspirin (£ 100mg) will be tolerated.
  • CRP >30 mg/dl, fever, current treatment with antibiotics, or chronic granulomatous infections (e.g. tuberculosis) in the history or on a screening chest X-ray.
  • Neutropenia or anemia (leucocyte count < 2.0x109 /l, hemoglobin <11g/dl for ma les or <10g/dl for females)
  • Pregnancy or breast-feeding. When appropriate (fertile women),anticonception for at last 3 month prior inclusion will be required.
  • Severe liver or renal disease ( AST or ALT>3 times the upper limit of normal laboratory range, serum creatinine >130mM)
  • Ongoing malignant neoplasm
  • Use of any investigational drug within 30 days of enrollment into the study or within 5 half-lives of the investigational drug (whichever is longer)
  • Immunosuppressive treatment or immunodeficient diseases.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00303394

Layout table for location information
Steno Diabetes Center
Gentofte, Copenhagen, Denmark, 2280
University Hospital of Zurich, Division of Endocrinology and Diabetes
Zurich, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Steno Diabetes Center Copenhagen
Layout table for investigator information
Study Chair: Marc Y Donath, MD University of Zurich
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00303394    
Other Study ID Numbers: EK-1000-ZH
First Posted: March 16, 2006    Key Record Dates
Last Update Posted: March 5, 2007
Last Verified: March 2007
Keywords provided by University of Zurich:
Type 2 Diabetes, IL-1, inflammation, glucotoxicity, insulin
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Interleukin 1 Receptor Antagonist Protein
Antirheumatic Agents